Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy (Molecular Imaging and Biology, (2018), 10.1007/s11307-018-1252-5)

Rudolf A. Werner; Harun Ilhan; Sebastian Lehner; László Papp; Norbert Zsótér; Imke Schatka; Dirk O. Muegge; Mehrbod S. Javadi; Takahiro Higuchi; Andreas K. Buck; Peter Bartenstein; Frank Bengel; Markus Essler; Constantin Lapa; Ralph A. Bundschuh

ArticleOPEN ACCESS

Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy (Molecular Imaging and Biology, (2018), 10.1007/s11307-018-1252-5)

Molecular Imaging and Biology

DOI: 10.1007/s11307-018-1261-4

1Citations

6Readers

Abstract

The article “Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy,” was originally published electronically on the publisher’s internet portal without open access.

Cite

CITATION STYLE

APA

Werner, R. A., Ilhan, H., Lehner, S., Papp, L., Zsótér, N., Schatka, I., … Bundschuh, R. A. (2018, December 1). Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy (Molecular Imaging and Biology, (2018), 10.1007/s11307-018-1252-5). Molecular Imaging and Biology. Springer New York LLC. https://doi.org/10.1007/s11307-018-1261-4

Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy (Molecular Imaging and Biology, (2018), 10.1007/s11307-018-1252-5)

Abstract

Cite

Register to see more suggestions